Tue Oct 01 08:14:36 UTC 2024: ## Hedge Fund Marshall Wace Increases Stake in Edgewise Therapeutics by Over 600%
**New York, NY -** Marshall Wace LLP, a prominent hedge fund, has significantly increased its holdings in Edgewise Therapeutics, Inc. (NASDAQ: EWTX) during the second quarter, according to the firm’s recent 13F filing with the Securities and Exchange Commission (SEC).
The investment firm boosted its stake in Edgewise by an impressive 661.2%, now owning 415,720 shares of the company’s stock. This substantial increase suggests a strong vote of confidence in Edgewise’s potential and its work in developing innovative treatments for debilitating diseases.
Edgewise Therapeutics is a clinical-stage biotechnology company focusing on the development of therapies that target the extracellular matrix (ECM) in various diseases. Their primary focus is on the treatment of rare and orphan diseases, including Duchenne muscular dystrophy and other neuromuscular disorders.
Marshall Wace’s significant investment in Edgewise signals growing interest from institutional investors in the company’s promising pipeline of treatments. This move could be a major boost for Edgewise, further solidifying its position in the pharmaceutical industry and attracting potential partnerships or collaborations.
First Piper 